Treatment of breast cancer
- PMID: 20521754
Treatment of breast cancer
Abstract
Understanding breast cancer treatment options can help family physicians care for their patients during and after cancer treatment. This article reviews typical treatments based on stage, histology, and biomarkers. Lobular carcinoma in situ does not require treatment. Ductal carcinoma in situ can progress to invasive cancer and is treated with breast-conserving surgery and radiation therapy without further lymph node exploration or systemic therapy. Stages I and II breast cancers are usually treated with breast-conserving surgery and radiation therapy. Radiation therapy following breast-conserving surgery decreases mortality and recurrence. Sentinel lymph node biopsy is considered for most breast cancers with clinically negative axillary lymph nodes, and it does not have the adverse effects of arm swelling and pain that are associated with axillary lymph node dissection. Choice of adjuvant systemic therapy depends on lymph node involvement, hormone receptor status, ERBB2 (formerly HER2 or HER2/neu) overexpression, and patient age and menopausal status. In general, node-positive breast cancer is treated systemically with chemotherapy, endocrine therapy (for hormone receptor-positive cancer), and trastuzumab (for cancer overexpressing ERBB2). Anthracycline- and taxane-containing chemotherapeutic regimens are active against breast cancer. Stage III breast cancer typically requires induction chemotherapy to downsize the tumor to facilitate breast-conserving surgery. Inflammatory breast cancer, although considered stage III, is aggressive and requires induction chemotherapy followed by mastectomy, rather than breastconserving surgery, as well as axillary lymph node dissection and chest wall radiation. Prognosis is poor in women with recurrent or metastatic (stage IV) breast cancer, and treatment options must balance benefits in length of life and reduced pain against harms from treatment.
Comment in
-
Life beyond breast cancer.Am Fam Physician. 2010 Jun 1;81(11):1330-2. Am Fam Physician. 2010. PMID: 20521750 No abstract available.
-
Information from your family doctor. Breast cancer treatment.Am Fam Physician. 2010 Jun 1;81(11):1347-9. Am Fam Physician. 2010. PMID: 20527363 No abstract available.
-
Complementary and alternative therapies for breast cancer.Am Fam Physician. 2011 Mar 1;83(5):502-6; author reply 507. Am Fam Physician. 2011. PMID: 21391514 No abstract available.
-
Complementary and alternative therapies for breast cancer.Am Fam Physician. 2011 Mar 1;83(5):507; author reply 507. Am Fam Physician. 2011. PMID: 21391515 No abstract available.
Similar articles
-
Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature.Breast Cancer Res Treat. 2008 Dec;112(3):513-21. doi: 10.1007/s10549-007-9880-5. Epub 2008 Feb 1. Breast Cancer Res Treat. 2008. PMID: 18240020
-
Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.Jpn J Clin Oncol. 2005 Mar;35(3):126-33. doi: 10.1093/jjco/hyi039. Jpn J Clin Oncol. 2005. PMID: 15741302
-
Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.Cancer. 2010 Mar 1;116(5):1243-51. doi: 10.1002/cncr.24887. Cancer. 2010. PMID: 20087958
-
[Management of the axilla in breast cancer: evidences and unresolved issues].Orv Hetil. 2001 Sep 9;142(36):1941-50. Orv Hetil. 2001. PMID: 11680099 Review. Hungarian.
-
Adjuvant therapy for breast cancer.NIH Consens Statement. 2000 Nov 1-3;17(4):1-35. NIH Consens Statement. 2000. PMID: 11512506 Review.
Cited by
-
Circulating tumor DNA: from discovery to clinical application in breast cancer.Front Immunol. 2024 Apr 30;15:1355887. doi: 10.3389/fimmu.2024.1355887. eCollection 2024. Front Immunol. 2024. PMID: 38745646 Free PMC article. Review.
-
Identification of the new molecular subtypes related to inflammation in breast cancer.Medicine (Baltimore). 2024 May 10;103(19):e38146. doi: 10.1097/MD.0000000000038146. Medicine (Baltimore). 2024. PMID: 38728446 Free PMC article.
-
A novel immune‑related lncRNA as a prognostic biomarker in HER2+ breast cancer.Oncol Lett. 2024 Apr 16;27(6):269. doi: 10.3892/ol.2024.14402. eCollection 2024 Jun. Oncol Lett. 2024. PMID: 38686356 Free PMC article.
-
Radiation Therapy for Breast Cancer in Africa.Adv Radiat Oncol. 2024 Mar 12;9(6):101488. doi: 10.1016/j.adro.2024.101488. eCollection 2024 Jun. Adv Radiat Oncol. 2024. PMID: 38681886 Free PMC article. Review.
-
Unraveling Drug Delivery from Cyclodextrin Polymer-Coated Breast Implants: Integrating a Unidirectional Diffusion Mathematical Model with COMSOL Simulations.Pharmaceutics. 2024 Apr 2;16(4):486. doi: 10.3390/pharmaceutics16040486. Pharmaceutics. 2024. PMID: 38675147 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous